<DOC>
	<DOCNO>NCT00992394</DOCNO>
	<brief_summary>This study propose compare 2 different method manage subject psoriasis achieve good disease control , define clinical response Physician Global Assessment ( PGA ) inferior equal 1 screen visit , etanercept treatment . The first method involve stop etanercept treatment entry study , option reinitiate etanercept 50 mg weekly medical review agreement subject investigator . The second method involve continue etanercept 25 mg weekly , option increase dose 50 mg weekly medical review agreement subject investigator . Subjects randomize one two study arm .</brief_summary>
	<brief_title>Study Comparing 2 Different Strategies For Management Subjects With Plaque Psoriasis Who Have Responded Etanercept</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Eighteen ( 18 ) year age old time consent . Previously treat etanercept chronic plaque psoriasis least 12 week prior screen visit receive total weekly dose 50 mg per week least 6 week precede day screen visit Having show clinical response PGA inferior equal 1 screen visit . PGA inferior equal 1 baseline visit . Evidence skin condition ( eg , eczema ) psoriasis would interfere evaluation effect study medication psoriasis . Evidence active previously know medical history inflammatory arthritis ( eg , rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis ) . Any biologics etanercept within 20 week prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Plaque psoriasis - etanercept - response maintenance</keyword>
</DOC>